In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

Eli Lilly’s stock took a 4.6% dive after Morgan Stanley gently tapped the brakes on its optimism, lowering its price target ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research ... Bernstein also reiterated a Buy rating on the stock with a $1,100.00 price ...

Given this stat line, it's not all that surprising that Lilly's stock price tends to move based ... Eisai actually revised its full-year 2024 forecast for Leqembi to 42.5 billion yen -- down ...